title: A higher body mass index and fat mass are factors predictive of docetaxel dose intensity.
abstract: BACKGROUND
  Few data are published on docetaxel toxicity in obese patients.
  
  
  METHODS
  All obese patients (n=100) treated for early breast cancer during three consecutive years at our Institution, were retrospectively investigated. The same number of non-obese patients was randomly selected and used as controls. We assessed the factors predictive of the relative dose intesity (RDI) reduction, including body composition.
  
  
  RESULTS
  A total of 18% (n=18) of obese patients and 5% (n=5) of non-obese patients required reduction of docetaxel RDI due to toxicity (p=0.008). In a multivariate analysis, body mass index (BMI) and age were predictive of a reduction in RDI. Among the 89 patients with a determination of body composition, patients with a higher fat mass more frequently had a reduction in docetaxel RDI (p=0.002). In multivariate analysis, fat mass was the only independent factor predictive of a reduction in docetaxel RDI.
  
  
  CONCLUSIONS
  Obese patients treated for early breast cancer more frequently required a reduction in docetaxel RDI. Fat mass seems to be the best factor predictive of a reduction in docetaxel RDI.
authors: Avenue General Harris 14000 Caen, France. sophiegouerant@hotmail.com.
authors: Sophie
authors: S
authors: Gouérant
authors: Marianne
authors: M
authors: Leheurteur
authors: Maher
authors: M
authors: Chaker
authors: Romain
authors: R
authors: Modzelewski
authors: Olivier
authors: O
authors: Rigal
authors: Corinne
authors: C
authors: Veyret
authors: Géraldine
authors: G
authors: Lauridant
authors: Florian
authors: F
authors: Clatot
mesh_terms: D000273:Adipose Tissue; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D015992:Body Mass Index; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008875:Middle Aged; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel
keywords: Early breast cancer; docetaxel; dose intensity; fat mass; obesity; toxicity